Litcius/Paper detail

Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia

Marie-Émilie Dourthe, Florence Rabian, Karima Yakouben, Florian Chevillon, Aurélie Cabannes‐Hamy, Françoise Méchinaud, Audrey Grain, Delphine Chaillou, Ilhem Rahal, Sophie Caillat‐Zucman, Emmanuelle Lesprit, J. Naudin, Julie Roupret‐Serzec, Nathalie Parquet, Anne Brignier, Valérie Guérin‐El Khourouj, Élodie Lainey, Aurélie Caye‐Eude, Hélène Cavé, Emmanuelle Clappier, Stéphanie Mathis, Élie Azoulay, Jean Hugues Dalle, Nathalie Dhédin, Isabelle Madelaine, Jérôme Larghero, Nicolas Boissel, André Baruchel

2021Leukemia151 citationsDOI

Topics & Concepts

MedicineBlinatumomabInternal medicineCumulative incidenceCytokine release syndromeMinimal residual diseaseAcute lymphocytic leukemiaGastroenterologyImmunologyOncologyRefractory (planetary science)ImmunotherapyLeukemiaLymphoblastic LeukemiaTransplantationCancerAstrobiologyChimeric antigen receptorPhysicsCAR-T cell therapy researchAcute Lymphoblastic Leukemia researchVirus-based gene therapy research
Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia | Litcius